Abstract
<p><span style="font-family: Calibri; font-size: medium;">The Minilab protocol is an excellent method of identifying falsified medicines, and two per cent (18 out of 899 samples) were falsified. However, as the data in this paper show, it considerably underestimates (by roughly 4.5%) the amount of substandard medicines in the market (roughly 12 per cent), especially among medicines made by Indian companies. In addition to considerable patient death, substandard antimicrobial medicines are likely to drive drug resistance. Policymakers should redouble efforts to identify and combat such medicines.</span></p>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
